342 related articles for article (PubMed ID: 29271782)
21. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.
Wei L; Wang FS; Zhang MX; Jia JD; Yakovlev AA; Xie W; Burnevich E; Niu JQ; Jung YJ; Jiang XJ; Xu M; Chen XY; Xie Q; Li J; Hou JL; Tang H; Dou XG; Gandhi Y; Hu WH; McPhee F; Noviello S; Treitel M; Mo L; Deng J
World J Gastroenterol; 2018 Mar; 24(12):1361-1372. PubMed ID: 29599611
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Sugimoto K; Kim SR; Kim SK; Imoto S; Tohyama M; Kim KI; Ohtani A; Hatae T; Yano Y; Kudo M; Hayashi Y
Oncology; 2015; 89 Suppl 2():42-6. PubMed ID: 26584035
[TBL] [Abstract][Full Text] [Related]
23. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
Suzuki F; Hatanaka N; Bando E; Nakamura K; Komoto A
Hepatol Int; 2018 May; 12(3):244-253. PubMed ID: 29900486
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
Kawakami Y; Ochi H; Hayes CN; Imamura M; Tsuge M; Nakahara T; Katamura Y; Kohno H; Kohno H; Tsuji K; Takaki S; Mori N; Honda Y; Arataki K; Takahashi S; Kira S; Tamura T; Masuda K; Nakamura T; Kikkawa M; Chayama K
J Gastroenterol; 2018 Apr; 53(4):548-556. PubMed ID: 28815329
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
[TBL] [Abstract][Full Text] [Related]
26. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
Izumi N; Yokosuka O; Kawada N; Osaki Y; Yamamoto K; Sata M; Ishikawa H; Ueki T; Hu W; McPhee F; Hughes EA; Kumada H
Antivir Ther; 2014; 19(5):501-10. PubMed ID: 24451151
[TBL] [Abstract][Full Text] [Related]
27. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
[TBL] [Abstract][Full Text] [Related]
28. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
[TBL] [Abstract][Full Text] [Related]
29. Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.
Bronowicki JP; Pol S; Thuluvath PJ; Larrey D; Martorell CT; Rustgi VK; Morris DW; Younes Z; Fried MW; Bourlière M; Hézode C; Reddy KR; Massoud O; Abrams GA; Ratziu V; He B; Eley T; Ahmad A; Cohen D; Hindes R; McPhee F; Reilly B; Mendez P; Hughes E
Antivir Ther; 2013; 18(7):885-93. PubMed ID: 23804631
[TBL] [Abstract][Full Text] [Related]
30. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
31. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
Tamori A; Hai H; Uchida-Kobayashi S; Enomoto M; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Teranishi Y; Yoshida K; Morikawa H; Murakami Y; Kawada N
Ann Hepatol; 2017; 16(5):734-741. PubMed ID: 28809743
[TBL] [Abstract][Full Text] [Related]
32. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Cho BW; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB
Clin Mol Hepatol; 2017 Mar; 23(1):51-56. PubMed ID: 28297836
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
35. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
McPhee F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Yu ML; Ahn SH; Ishikawa H; Bhore R; Zhou N; Hernandez D; Mendez P; Kumada H
Adv Ther; 2015 Jul; 32(7):637-49. PubMed ID: 26155891
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
[TBL] [Abstract][Full Text] [Related]
37. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
Moreno C; Hezode C; Marcellin P; Bourgeois S; Francque S; Samuel D; Zoulim F; Grange JD; Shukla U; Lenz O; Ouwerkerk-Mahadevan S; Fevery B; Peeters M; Beumont M; Jessner W
J Hepatol; 2015 May; 62(5):1047-55. PubMed ID: 25596313
[TBL] [Abstract][Full Text] [Related]
39. Preliminary study of two antiviral agents for hepatitis C genotype 1.
Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
[TBL] [Abstract][Full Text] [Related]
40. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
